Osteoid osteoma

Osteoid osteoma is a benign osteoblastic neoplasm characterized by a small, highly vascular nidus of osteoid and woven bone surrounded by a zone of reactive sclerosis.[1][2] The tumor is self-limiting, lacks aggressive growth potential, and is not premalignant.[2][3] In the jaws, osteoid osteoma is rare; the mandible is affected more often than the maxilla, and the condylar/temporomandibular joint (TMJ) region is a recognized site.[4][5] Pain is driven by markedly elevated prostaglandin E2 and prostacyclin production within the nidus, mediated predominantly through cyclooxygenase-2 (COX-2) expressed by tumor osteoblasts.[6][7] This prostaglandin-mediated mechanism accounts for the characteristic relief with nonsteroidal anti-inflammatory drugs (NSAIDs).[6][8] The signature imaging pattern is a small radiolucent nidus.[1][9] Complete surgical excision or percutaneous ablation of the nidus is curative.[1][2]

The 2020 WHO Classification of Soft Tissue and Bone Tumours retains osteoid osteoma as a distinct benign bone-forming neoplasm, classified separately from osteoblastoma despite shared histologic features and overlapping FOS/FOSB rearrangements; the two entities are distinguished by clinical presentation, radiologic behavior, and an arbitrary size threshold of 20 mm.[2][10] The term "osteoid osteoma" is standard and universally accepted. No synonyms are in routine clinical use. The lesion should not be confused with osteoma, which is a different entity with distinct clinical, histologic, and imaging characteristics.[11]

• Osteoid osteoma is the third most common benign bone tumor overall, accounting for approximately 11% of all benign osseous neoplasms.[1][12]
• Peak incidence occurs in the second decade of life, with a strong male predominance (male-to-female ratio approximately 2–3:1).[1][2]
• The femur and tibia are the most common sites; the jaws are rarely affected.[1][13]
• A literature review identified approximately 20 jaw cases by 2013, with additional sporadic reports since. The mandible—particularly the posterior body, ramus, and condyle—is involved more frequently than the maxilla. The TMJ/condylar region is a recognized but uncommon subsite.[4][5][14]

Symptoms

• The hallmark is persistent, often nocturnal pain that characteristically responds to aspirin or NSAIDs. In the jaws, however, the classic nocturnal pain pattern may be less pronounced or absent, contributing to diagnostic delay.[1][2][4]
• Pain may be localized to the affected jaw, the TMJ, or may mimic toothache when the lesion is near the alveolar process. TMJ-region lesions can present with chronic preauricular pain, limited mouth opening, or symptoms resembling temporomandibular disorder.[4][14][15]
• Duration of symptoms before diagnosis is often prolonged (months to years), reflecting the rarity of the jaw location and nonspecific presentation.[4][14]

Examination findings

• Localized bony swelling or tenderness may be present, particularly in cortical or subcortical lesions of the mandibular body.[5][13]
• Overlying soft tissue is typically normal. Trismus or mandibular asymmetry may occur with condylar involvement.[4]

Tempo and complications

• Growth is self-limited; the nidus rarely exceeds 1.5 cm. Spontaneous regression over 2–6 years has been documented in long bones, though jaw-specific natural history data are limited.[1][2]
• Misdiagnosis as odontogenic infection, temporomandibular disorder, or other jaw pathology is a recognized pitfall that may lead to unnecessary dental procedures.[4][15]

Location and distribution

• In the jaws, osteoid osteoma most commonly involves the posterior mandible (body, ramus, condyle), with occasional maxillary involvement. Lesions are typically intracortical or arise at the cortical–medullary junction.[4][5][9][14]
• The alveolar process may be involved, and rare cases present in close association with tooth roots.[15]

Periphery and shape

• The nidus is characteristically round to oval and well-defined.[4][9]
• A surrounding zone of dense reactive osteosclerosis is the hallmark peripheral finding, often appearing as marked cortical thickening on cross-sectional imaging. On panoramic radiographs, the sclerotic reaction may appear as diffuse, ill-defined radiopacity that can obscure the nidus.[1][9][14]

Internal architecture

• The nidus appears as a small radiolucent focus, commonly less than 1–1.5 cm in diameter. Variable degrees of central mineralization within the nidus are common, ranging from a purely lucent center to a partially or densely calcified core.[1][9][16]
• On panoramic radiography, the nidus may be difficult to identify because of superimposition of the surrounding sclerosis and adjacent anatomic structures.[14]
• Cross-sectional imaging (CBCT or CT) is far more sensitive for demonstrating the nidus and its internal calcification pattern, and is considered essential when conventional radiography is nondiagnostic. CBCT can delineate the nidus within the surrounding sclerotic bone and clarify the relationship to the cortex and medullary space.[14][17][18][19]

Effects on teeth and adjacent structures

• When the lesion is near the alveolar process, widening of the periodontal ligament space, displacement of adjacent teeth, or external root resorption may occasionally be observed.[5][15]
• Periosteal reaction along the adjacent cortex has been reported, particularly in mandibular body lesions.[5]

Cortical involvement and extent

• The lesion is typically intracortical, with fusiform cortical thickening surrounding the nidus. Cortical expansion may be present but is usually modest.[9][14]
• Extension into the medullary space occurs occasionally; purely medullary (cancellous) or subperiosteal variants are recognized in the general skeleton but are rare in the jaws.[9][16]

Variants

• Multifocal nidi within a single jaw lesion have been reported as an exceptional variant; a case with four discrete nidi in the posterior mandible is the only documented example in the jaw literature.[5]
• Intra-articular presentation in the TMJ condyle is a recognized variant that may lack prominent surrounding sclerosis, paralleling the behavior of intra-articular osteoid osteomas elsewhere in the skeleton.[4][20]

Bone scintigraphy

• Technetium-99m bone scintigraphy demonstrates intense focal uptake at the nidus, often with a characteristic "double-density" sign (focal hot spot within a larger area of increased activity). This modality is highly sensitive and has been used in jaw cases to confirm the metabolically active nature of the lesion and to differentiate it from quiescent sclerotic conditions.[4][14][21]

Medical CT

• Non-contrast CT is considered the optimal imaging modality for suspected osteoid osteoma per ACR Appropriateness Criteria, providing superior nidus detection and delineation compared with MRI. In the jaws, CT precisely localizes the nidus within cortical or medullary bone and demonstrates the degree of surrounding sclerosis.[4][14][17]

MRI

• MRI may show extensive bone marrow edema and soft-tissue signal changes that can obscure the nidus and mimic aggressive pathology. The nidus may be missed on standard sequences in up to 35% of cases. Dynamic contrast-enhanced MRI improves nidus conspicuity, with peak enhancement typically in the arterial phase. MRI is most useful when an alternative diagnosis (e.g., osteomyelitis, malignancy) must be excluded.[17][21]

Hybrid imaging

• SPECT/CT with Tc-99m bisphosphonates and PET/CT with F-18 sodium fluoride combine metabolic sensitivity with anatomic detail and can be valuable in diagnostically challenging cases. FDG-PET is generally not recommended, as osteoid osteoma is typically FDG-negative.[21]

Osteoid osteoma in the jaws enters the differential of a small, painful sclerotic or mixed lesion, particularly in a young patient. The key diagnostic task is identifying the nidus; without it, the surrounding sclerosis alone is nonspecific.

The highest-risk diagnostic pitfall is failure to identify the nidus on conventional radiography, leading to misdiagnosis as chronic osteomyelitis or odontogenic pathology and resulting in unnecessary dental extractions or prolonged antibiotic therapy.[4][14][15] Cross-sectional imaging (CT or CBCT) should be obtained whenever a small painful sclerotic jaw lesion is encountered in a young patient, and histopathologic confirmation is essential.

Nidus

• The nidus is the diagnostic structure, composed of irregularly arranged trabeculae of osteoid and woven bone rimmed by prominent, plump osteoblasts set within a richly vascularized loose fibrous stroma.[2][11][13]
• Osteoclasts are interspersed among the trabeculae. The osteoid seams are often wide, reflecting the excessive production of unmineralized bone matrix.[2][13]
• Nerve fibers positive for S-100 protein and protein gene product 9.5 (PGP 9.5) are present within and around the nidus, particularly in perivascular locations, contributing to pain generation.[24]

Surrounding bone

• The reactive zone consists of dense lamellar sclerotic bone sharply demarcated from the nidus. This sclerotic shell does not contain tumor and is not diagnostically specific.[2][11]

Radiologic-pathologic correlation

• The radiolucent nidus on imaging corresponds to the vascular osteoid-rich tissue; central calcification within the nidus corresponds to areas of mineralized woven bone trabeculae.[9][13]

Molecular findings

• FOS rearrangements (and less commonly FOSB rearrangements) have been identified in osteoid osteoma and osteoblastoma, confirming a close biologic relationship. FISH for FOS rearrangement and FOS immunohistochemistry are emerging as valuable ancillary tools to distinguish these tumors from osteosarcoma in diagnostically challenging cases.[10]
• COX-2 is strongly expressed by tumor osteoblasts within the nidus, with minimal expression in surrounding reactive bone, providing the molecular basis for prostaglandin-mediated pain and NSAID responsiveness.[6]

Initial evaluation and referral

• When a painful sclerotic jaw lesion is identified on panoramic radiography, cross-sectional imaging (CT or CBCT) should be obtained to confirm the presence and location of the nidus.[14][17]
• Referral to an oral and maxillofacial surgeon is appropriate once imaging is suggestive. Bone scintigraphy may be considered in equivocal cases.[4][14]

Conservative management

• NSAIDs are the first-line treatment and may be continued long-term, as the tumor tends to regress spontaneously over 2–6 years. COX-2 inhibitors have demonstrated equivalent or superior pain control compared with aspirin in the general orthopedic literature.[1][2][8]

Surgical treatment

• Surgical excision (curettage or en bloc resection) is indicated when pain is refractory to NSAIDs, prolonged NSAID use is not tolerated, or the patient declines expectant management.[1][2]
• Complete removal of the nidus is essential; incomplete excision is the primary cause of recurrence.[12][25]
• In the jaws, marginal or segmental resection has been employed depending on lesion size and location, with immediate and complete pain relief reported following successful nidus removal.[4][5][13]

Percutaneous ablation

• Radiofrequency ablation (RFA) is the preferred minimally invasive technique in the appendicular skeleton, with success rates comparable to open surgery. Its application in the jaws is limited by proximity to the inferior alveolar nerve, tooth roots, and the TMJ; case-by-case assessment of feasibility is required.[1][3][25][26]

Recurrence and prognosis

• Recurrence rates after complete surgical excision in the general skeleton range from approximately 5–10% for primary lesions; RFA carries similar recurrence rates of 5–12%. Higher recurrence rates have been reported in pediatric cohorts.[12][25][27]
• Prognosis is excellent. The tumor is not premalignant, and recurrence is effectively managed with repeat excision or ablation, with overall cure rates approaching 97% after second-line treatment.[3][12]
• Long-term follow-up with clinical assessment and imaging is advisable to detect early recurrence, particularly in the first 1–2 years after intervention.[12]